N-Tricosanoyl-4,5-dihydroxytryptamine



Compound IDCDAMM01746
Common nameN-Tricosanoyl-4,5-dihydroxytryptamine
IUPAC nameN-[2-(4,5-dihydroxy-1H-indol-3-yl)ethyl]tricosanamide
Molecular formulaC33H56N2O3

Experimental data

Retention time16.93
Adduct[M+Na]+
Actual mz551.417
Theoretical mz551.418
Error2.57
Ionizaton modePositive
Instrument typeLC-MS/MS-QTOF, spectrum predicted by MS-DIAL v4.9 integrated with MS-FINDER 3.60
Score6.5671

Identifiers and class information

Inchi keyBZGLLDHAEHVDCQ-UHFFFAOYSA-N
SmilesO=C(NCCC1=CNC=2C=CC(O)=C(O)C21)CCCCCCCCCCCCCCCCCCCCCC
SuperclassOrganoheterocyclic compounds
ClassIndoles and derivatives

Pharmacokinetic properties

Number of descriptor values(#stars)11
Number of non-conjugated amine groups (#amine)0
Number of amidine and guanidine groups (#amidine)0
Number of carboxylic acid groups (#acid)0
Number of non-conjugated amide groups (#amide)1
Number of rotatable bonds (#rotor)26
Number of reactive functional groups (#rtvFG)0
Predicted central nervous system activity (CNS)-2
Molecular weight (mol_MW)528.817
Computed dipole moment(dipole)6.339
Total solvent accessible surface area (SASA)1150.06
Hydrophobic component of SASA (FOSA)858.194
Hydrophilic component of SASA (FISA)141.094
Pie component of the SASA (PISA)150.767
Weakly polar component of the SASA (WPSA)0
Total solvent accesible volume (volume)2037.45
Number of hydrogen bond donors (donorHB)4
Number of hydrogen bond acceptors (accptHB)4
Free energy of solvation of dipole (dip^2/V)0.0197235
Index of cohesive interaction in solids (ACxDN^.5/SA)0.0069562
Globularity descriptor (glob)0.675831
Predicted polarizability in cubic angstroms (QPpolrz)60.13
Predicted hexadecane/gas partition coefficient (QPlogPC16)21.736
Predicted octanol/gas partition coefficient (QPlogPoct)27.047
Predicted water/gas partition coefficient (QPlogPw)9.87
Predicted octanol/water partition coefficient (QPlogPo/w)8.323
Predicted aqueous solubility (QPlogS)-10.175
Conformation-independent predicted aqueous solubility (CIQPlogS)-7.893
Predicted IC50 value for blockage of HERG K+ channels (QPlogHERG)-6.122
Predicted apparent Caco-2 cell permeability in nm/sec (QPPCaco)326.828
Predicted brain/blood partition coefficient (QPlogBB)-3.063
Predicted apparent MDCK cell permeability in nm/sec (QPPMDCK)211.147
Predicted skin permeability, log Kp (QPlogKp)-1.092
PM3 calculated ionization potential (IP(ev))7.801
PM3 calculated electron affinity (EA(eV))-0.135
Number of likely metabolic reactions (#metab)5
Prediction of binding to human serum albumin (QPlogKhsa)1.599
Predicted qualitative human oral absorption (HumanOralAbsorption)1
Predicted human oral absorption on 0 to 100% scale (PercentHumanOralAbsorption)94.762
Solvent-accessible surface area of fluorine atoms (SAFluorine)0
Solvent-accessible surface area of amide oxygen atoms (SAamideO)18.038
Van der Waals surface area (PSA)94.278
Number of nitrogen and oxygen atoms (#NandO)5
Number of violations of Lipinski’s rule of five (RuleOfFive)2
Number of violations of Jorgensen’s rule of three (RuleOfThree)1

Compound-target network

Cytoscape Graph

Protein targets associated with phytocompound

Uniprot ID Gene name Target name TTD_ID Prediction source
P22303ACHEAcetylcholinesteraseT30082SEA
P16083NQO2Quinone reductase 2T75498SEA
P21554CNR1Cannabinoid receptor 1 (by homology)T76685SEA
P34913EPHX2Epoxide hydrataseT35734SEA
P28222HTR1BSerotonin 1b (5-HT1b) receptorT07806SEA
P28221HTR1DSerotonin 1d (5-HT1d) receptorT11072SEA
P05164MPOMyeloperoxidaseT23471SEA
O00519FAAHAnandamide amidohydrolaseT11754SEA
Q8NER1TRPV1Vanilloid receptorT83193SEA
P06746POLBDNA polymerase beta (by homology)T06958SEA
P06276BCHEButyrylcholinesteraseT99799SEA
P48039MTNR1AMelatonin receptor 1AT97613SEA
P49286MTNR1BMelatonin receptor 1BT48268SEA
P34972CNR2Cannabinoid receptor 2T37693SEA
Q13093PLA2G7LDL-associated phospholipase A2T69912SEA
P30939HTR1FSerotonin 1f (5-HT1f) receptorT78656SEA
Q13822ENPP2AutotaxinT63512SEA
Q9HBW0LPAR2Lysophosphatidic acid receptor Edg-4T39380SEA
P28336NMBRNeuromedin B receptorT68887SEA
P37840SNCAAlpha-synucleinT03644SEA
P28336NMBRNeuromedin B receptorT68887SEA
Q969S8HDAC10Histone deacetylase 10T94324SEA
Q92633LPAR1Lysophosphatidic acid receptor Edg-2T92640SEA
O60603TLR2Toll-like receptor 2T82078SEA
P47870GABRB2GABA(A) receptor beta-2T80387SEA
P35270SPRSubstance-P receptorT47094SEA

Target associated diseases

TTD_ID Disease_ID Disease name ICD_11 Uniprot ID Gene names
T30082DI0025Alzheimer disease[ICD-11: 8A20]P22303ACHE
T30082DI0166Glaucoma[ICD-11: 9C61]P22303ACHE
T30082DI0282Myasthenia gravis[ICD-11: 8C6Y]P22303ACHE
T30082DI0313Oesophageal/gastroduodenal disorder[ICD-11: DD90]P22303ACHE
T30082DI0332Pediculosis[ICD-11: 1G00]P22303ACHE
T30082DI0421Unspecific substance harmful effect[ICD-11: NE6Z]P22303ACHE
T75498DI0214Insomnia[ICD-11: 7A00-7A0Z]P16083NQO2
T76685DI0031Anorexia nervosa[ICD-11: 6B80]P21554CNR1
T76685DI0214Insomnia[ICD-11: 7A00-7A0Z]P21554CNR1
T76685DI0308Obesity[ICD-11: 5B80-5B81]P21554CNR1
T35734DI0086Chronic obstructive pulmonary disease[ICD-11: CA22]P34913EPHX2
T35734DI0190Hypertension[ICD-11: BA00-BA04]P34913EPHX2
T07806DI0264Migraine[ICD-11: 8A80]P28222HTR1B
T07806DI0337Pituitary gland disorder[ICD-11: 5A60-5A61]P28222HTR1B
T07806DI0354Psychotic disorder[ICD-11: 6A20-6A25]P28222HTR1B
T07806DI0370Schizophrenia[ICD-11: 6A20]P28222HTR1B
T11072DI0264Migraine[ICD-11: 8A80]P28221HTR1D
T11072DI0337Pituitary gland disorder[ICD-11: 5A60-5A61]P28221HTR1D
T23471DI0229Left ventricular failure[ICD-11: BD11]P05164MPO
T23471DI0339Postoperative inflammation[ICD-11: 1A00-CA43]P05164MPO
T11754DI0101Corneal disease[ICD-11: 9A76-9A78]O00519FAAH
T83193DI0163General pain disorder[ICD-11: 8E43]Q8NER1TRPV1
T06958DI0391Solid tumour/cancer[ICD-11: 2A00-2F9Z]P06746POLB
T99799DI0324Pain[ICD-11: MG30-MG3Z]P06276BCHE
T99799DI0411Tonus and reflex abnormality[ICD-11: MB47]P06276BCHE
T97613DI0214Insomnia[ICD-11: 7A00-7A0Z]P48039MTNR1A
T48268DI0214Insomnia[ICD-11: 7A00-7A0Z]P49286MTNR1B
T37693DI0040Attention deficit hyperactivity disorder[ICD-11: 6A05]P34972CNR2
T37693DI0214Insomnia[ICD-11: 7A00-7A0Z]P34972CNR2
T69912DI0025Alzheimer disease[ICD-11: 8A20]Q13093PLA2G7
T69912DI0035Arterial occlusive disease[ICD-11: BD40]Q13093PLA2G7
T69912DI0070Cardiovascular disease[ICD-11: BA00-BE2Z]Q13093PLA2G7
T78656DI0264Migraine[ICD-11: 8A80]P30939HTR1F
T78656DI0337Pituitary gland disorder[ICD-11: 5A60-5A61]P30939HTR1F
T63512DI0199Idiopathic interstitial pneumonitis[ICD-11: CB03]Q13822ENPP2
T68887DI0062Breast cancer[ICD-11: 2C60-2C6Y]P28336NMBR
T68887DI0391Solid tumour/cancer[ICD-11: 2A00-2F9Z]P28336NMBR
T03644DI0025Alzheimer disease[ICD-11: 8A20]P37840SNCA
T03644DI0044Autonomic nervous system disorder[ICD-11: 8D87]P37840SNCA
T03644DI0331Parkinsonism[ICD-11: 8A00]P37840SNCA
T68887DI0062Breast cancer[ICD-11: 2C60-2C6Y]P28336NMBR
T68887DI0391Solid tumour/cancer[ICD-11: 2A00-2F9Z]P28336NMBR
T94324DI0391Solid tumour/cancer[ICD-11: 2A00-2F9Z]Q969S8HDAC10
T92640DI0146Fibrosis[ICD-11: GA14-GC01]Q92633LPAR1
T92640DI0199Idiopathic interstitial pneumonitis[ICD-11: CB03]Q92633LPAR1
T92640DI0351Psoriasis[ICD-11: EA90]Q92633LPAR1
T92640DI0399Systemic sclerosis[ICD-11: 4A42]Q92633LPAR1
T82078DI0346Prostate cancer[ICD-11: 2C82]O60603TLR2
T80387DI0117Depression[ICD-11: 6A70-6A7Z]P47870GABRB2
T80387DI0214Insomnia[ICD-11: 7A00-7A0Z]P47870GABRB2
T80387DI0256Mental/behavioural/neurodevelopmental disorder[ICD-11: 6E20-6E8Z]P47870GABRB2
T80387DI0411Tonus and reflex abnormality[ICD-11: MB47]P47870GABRB2
T47094DI0117Depression[ICD-11: 6A70-6A7Z]P35270SPR
T47094DI0293Nausea/vomiting[ICD-11: MD90]P35270SPR

Copyright © 2025